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Abstract
Background: Late cerebral ischemia carries high morbidity and mortality after subarachnoid hemorrhage (SAH)
due to reduced cerebral blood flow (CBF) and the subsequent cerebral ischemia which is associated with
upregulation of contractile receptors in the vascular smooth muscle cells (SMC) via activation of mitogen-activated
protein kinase (MAPK) of the extracellular signal-regulated kinase (ERK)1/2 signal pathway. We hypothesize that SAH
initiates cerebrovascular ERK1/2 activation, resulting in receptor upregulation. The raf inhibitor will inhibit the
molecular events upstream ERK1/2 and may provide a therapeutic window for treatment of cerebral ischemia after
SAH.
Results: Here we demonstrate that SAH increases the phosphorylation level of ERK1/2 in cerebral vessels and
reduces the neurology score in rats in additional with the CBF measured by an autoradiographic method. The
intracisternal administration of SB-386023-b, a specific inhibitor of raf, given 6 h after SAH, aborts the receptor
changes and protects the brain from the development of late cerebral ischemia at 48 h. This is accompanied by
reduced phosphorylation of ERK1/2 in cerebrovascular SMC. SAH per se enhances contractile responses to
endothelin-1 (ET-1), 5-carboxamidotryptamine (5-CT) and angiotensin II (Ang II), upregulates ETB, 5-HT1B and AT1
receptor mRNA and protein levels. Treatment with SB-386023-b given as late as at 6 h but not at 12 h after the
SAH significantly decreased the receptor upregulation, the reduction in CBF and the neurology score.
Conclusion: These results provide evidence for a role of the ERK1/2 pathway in regulation of expression of
cerebrovascular SMC receptors. It is suggested that raf inhibition may reduce late cerebral ischemia after SAH and
provides a realistic time window for therapy.
Background
The clinical syndrome of delayed cerebral ischemia after
rupture of a cerebral aneurysm includes recurrent bleed-
ing from the aneurysm, angiographic evidence of cere-
bral arterial constriction, ischemic deterioration and is
associated with high morbidity. Early surgery or angio-
graphic coiling stops the bleeding but still carries high
ischemic morbidity; on the other hand late surgery has
lower ischemic morbidity but a higher overall mortality,
which makes the choice of treatment difficult. Over 300
pharmaceutical agents have been used in unsuccessful
attempts to reverse the cerebral vascular narrowing that
can be seen after subarachnoid hemorrhage (SAH) (also
referred to as vasospasm) and to improve outcome of
the patients [1]. Current treatment consists of neurocri-
tical care, measures to prevent and minimize secondary
brain injury, calcium channel blockers, and hemody-
namic management and endovascular therapies. These
manoeuvres are however expensive, time-consuming
and only partly effective [2]. The search continues for
agents that will prevent or alleviate the cerebral ische-
mia after SAH.
Several theories have appeared to explain the mechan-
i s m sr e s p o n s i b l ef o rt h el a t ec e r e b r a li s c h e m i aa f t e r
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any medium, provided the original work is properly cited.SAH, e.g. enhanced levels of free radicals [3-5], central
nervous system dysfunction [6,7], reduced levels of
endothelial relaxing factors [8-10], increased levels of
inflammatory mediators [11] and increased amounts of
vasoconstrictor substances such as endothelin (ET) [12]
and 5-hydroxytryptamine (5-HT) [13,14].
We have recently suggested that many of these
mechanisms are inter related and may share a common
signal-transduction pathway. SAH may cause enhanced
expression of endothelin type B receptor (ETB), 5-hydro-
xytryptaimine type 1B receptor (5-HT1B) and angioten-
sin type 1 (AT1) receptors, and of genes for cytokines
and metalloproteinases [15]. These genes are transcribed
via activation of mitogen-activated protein kinases
(MAPKs), in particular of the extracellular signal-regu-
lated 1/2 (ERK1/2) kinase pathway that acts via specific
transcription factors to result in their protein expression
[16]. We and others have shown that the upstream
MEK1/2 inhibitor U0126 can reduce the ERK1/2 activity
and the infarct volume after middle cerebral artery
occlusion (MCAO) in rat [17,18]. Raf is active upstream
of MEK and acts specifically to regulate the MEK/
ERK1/2 pathway. In experimental studies we have
reported that the raf inhibitor SB386023-b effectively
blocks pERK1/2 expression and attenuates the cerebro-
vascular receptor upregulation both on functional and
molecular levels [19].
Here we suggest that administration of the specific
and potent raf inhibitor SB386023-b prevents contractile
receptor upregulation and the development of late cere-
bral ischemia. The selective and potent raf inhibitor
SB386023-b has been demonstrated to inhibit both c-
Raf and B-Raf at 1-10 μM in a variety of cellular assays,
without affecting Jun N-terminal Kinase (JNK) or p38
[20]. We suggest that the late cerebral ischemia and the
cerebral blood flow (CBF) reduction are the result of
upregulation of receptors in the vascular smooth muscle
cells (SMC) that occur via activation of the ERK1/2
pathway. We suggest as a hypothesis that SB386023-b,
given at 0 and 6 h after the SAH improves the neurol-
ogy outcome, normalizes regional CBF and cerebrovas-
cular receptor upregulation.
Results
SAH model
SAH was induced by injecting 250 μl blood into the pre-
chiasmatic cistern in the rat. The raf inhibitor SB-
386023-b was injected intracisternally in our rat model
at 0, 6, or 12 hours after the SAH.
The total number of rats used in the study was 71; 12
in the sham group, 15 in the SAH + vehicle group, 9 in
the SAH group and 35 was used in the SAH + treat-
ment with SB386023-b groups. The mortality rate was
8% and the animals died during the follow up, there was
no difference in the mortality rate between the groups.
The rats did not show any distressed behaviour. They
were moving around normally, eating and drinking. All
surviving animals were neurologically examined using
an established scoring system [21,22] (Table 1). All SAH
+ vehicle animals and SAH animals treated with
SB386023-b after 12 h received a score of 1, and the
sham animals and SAH animals treated with SB386023-
b after 0 and 6 h got a score of 0.
In all operated rats, mean arterial blood pressure (105 ±
3 mmHg), partial pCO2 (38 ± 3 mmHg), partial pO2 (108
± 4 mmHg), hematocrit (39 ± 1 mmHg) values and tem-
perature were within acceptable limits during the opera-
tion. No statistical difference was seen in physiological
parameters between the groups; sham, SAH + vehicle
(henceforth only mentioned as SAH) and SAH treated
with SB386023-b at the different time points. As a result
of injecting the blood the cortical blood flow dropped
over both hemispheres to 10 ± 5% of resting flow (there
was no difference between the two Laser Doppler probe
data) and the intracranial pressure (ICP) increased from
9 ± 2 to 126 ± 9 mmHg. The Laser Doppler blood flow
and the elevated ICP returned to the basal values within
one hour of postoperative monitoring. There was no dif-
ference between the SAH groups.
Acute effects of the raf inhibitor SB386023-b on CBF, ICP
and functional responses
The acute effects of the raf inhibitor SB386023-b on
CBF, ICP and functional responses was investigated.
There were no immediate changes in the cortical CBF
or the ICP (within the first 2-3 h) when SB386023-b was
administrated at 0 h or 6 h after the SAH (Figure 1A-B).
In addition, there were no difference in the local cortical
blood flow response and ICP during the acute phase
between the groups SAH and SAH treated with
SB386023-b. This shows that the raf inhibitor SB386023-
b has no acute effect on the cortical CBF and ICP.
To study if the raf inhibitor has a direct vasomotor
effect on cerebral blood vessels, isolated ring segments
of the MCA were studied in a myograph. The functional
data shows that SB386023-b had no effect on the con-
tractility when it was applied in increasing
Table 1 Neurological score after SAH
Score Interpretation
0 No visible deficits
1 Contralateral forelimb flexion, when hold by tail
2 Decreased grip of contralateral forelimb
3 Spontaneous movement in all directions, but contralateral
circling if pulled by tail
4 Spontaneous contralateral circling
5 Death
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1C). In artery segments precontracted with 5-HT,
SB386023-b tended to relax the MCA slightly but the
effect was not significant at any concentration (at 10
-5
M the relaxant effect was 3 ± 2%).
Regional cerebral blood flow (rCBF) to evaluate the
overall consequences of SAH
The regional and global CBF was investigated by an
autoradiographic method in the various groups; sham,
SAH and SAH treated with SB386023-b.
There was a significant global decrease in cerebral
b l o o df l o wm e a s u r e da t4 8hi nt h eS A H( n=6 )g r o u p
as compared to the control sham group (n = 6) from
1 4 0±6t o6 3±2m l / 1 0 0g / m i n .T r e a t m e n tw i t h
SB386023-b, starting at 0 h and 6 h after the SAH, pre-
vented the reduction in CBF seen after SAH (Figure 2)
but not at 12 h (110 ± 20 ml/100 g/min, n = 3). The
SAH animals showed a reduction in the regional CBF in
15 of the 18 brain regions examined compared to the
Figure 1 Illustration of the cortical blood flow measured with laser Doppler flowmetry (A) and ICP (B) at the time of administration of
SB386023-b and injection of blood.( C) Concentration response curves elicited by cumulative application of SB386023-b in rat cerebral arteries.
Figure 2 Effect of treatment with the raf inhibitor SB386023-b
on the global CBF after induced SAH in rats. There is a
reduction in the global CBF in the SAH compared to the control
rats. Treatment with SB386023-b inhibited this reduction in CBF.
Data were obtained by an autoradiographic method and data are
expressed as mean ± s.e.m. values, *** P < 0.001. Statistical analyses
were performed using Kruskal-Wallis non-parametric test together
with Dunn’s post-hoc test.
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SB386023-b in conjunction with the SAH at 0 and after
6 h of SAH prevented this reduction in rCBF and there
was no difference as compared to the control group for
any of the regions studied. Treatment with SB386023-b
administered at 12 h after induction of SAH did not
prevent this reduction in rCBF (data not shown).
Functional in vitro pharmacology
K
+ -induced contractions did not differ significantly
between the cerebral arteries from the different groups
(Table 3 and 4). The Emax and pEC50 values for respec-
tive groups are presented in Table 3 and 4.
Contractile response to ET-1
In the middle cerebral artery (MCA) and basilar artery
(BA) from SAH rats (n = 6) ET-1 showed a leftward
shift of the concentration-response curve which indi-
cates an enhanced contractile response to ET-1 as
compared to the sham-operated rats (n = 6) where a
sigmoid curve was obtained (Figure 3A, Table 3).
Treatment with SB386023-b starting at 0 and 6 h after
SAH produced a significantly attenuated ET-1 induced
response, compared to the rats with induced SAH.
Interestingly there was no significant difference in the
contractile response between sham and SB386023-b
g i v e na t0a n d6ha f t e rS A H( F i g u r e3 A ,T a b l e3 ) .
When the SB386023-b treatment was begun at 12 h
after the induced SAH the responses did not
differ from that seen in animals receiving only SAH
(Table 3).
Contractile response to 5-CT
5-CT gave rise to a biphasic concentration-dependent
contraction, indicating the presence of the two 5-HT
receptor subtypes 5-HT1B and 5-HT2A as verified by
previous detailed antagonist studies [23]. This has been
confirmed using GR 55562, a selective 5-HT1B receptor
antagonist, shifting the high-affinity phase to the right
and removing the 5-HT1B component of the low-affinity
phase [24].
In both MCA and BA from rats with induced SAH (n =
5-6) 5-CT gave rise to an elevated Emax(1),E m a x (2) and
pEC50(2) as compared to the sham-operated rats (n = 5-6)
(p < 0.05, Figure 3B; Table 3). In BA treatment in vivo
with SB386023-b starting at 0 h and 6 h after SAH showed
down regulated responses, both the first 5-HT1B and the
second 5-HT2A phases were lower as compared to rats
with induced SAH (Figure 3B). In the MCA treatment
with SB386023-b at 0 h and 6 h after the SAH showed sig-
nificantly reduced Emax(1) (p < 0.05) and tended to a
decrease in the Emax(2),p E C 50(1) and pEC50(2) as com-
pared to SAH (Table 3). SB386023-b treatment given 12 h
after the induced SAH did not show attenuated contractile
response as compared to SAH (Figure 3B, Table 3).
Contractile response to Ang II
In MCA from rats with induced SAH (n = 6) Ang II (act-
ing via AT1 receptors) induced a concentration-dependent
Table 2 Regional cerebral blood flow 48 hours post subarachnoid hemorrhage
Control SAH SAH + SB386023-b
after 0 hours
SAH + SB386023-b
after 6 hours
frontal cortex 141 ± 16
a 75 ± 20
a, b 132 ± 17
b 135 ± 19
b
parietal cortex 169 ± 30
a 68 ± 14
a, b 141 ± 28
b 132 ± 30
b
occiptal cortex 137 ± 17
a 67 ± 21
a, b 141 ± 20
b 155 ± 21
b
caudate putamen 131 ± 17
a 71 ± 20
a, b 129 ± 16
b 142 ± 18
b
Septum 115 ± 24
a 60 ± 20
a, b 104 ± 18 128 ± 20
b
hippocampus 147 ± 25
a 52 ± 11
a, b 88 ± 13
b 85 ± 20
b
Thalamus 120 ± 16
a 64 ± 16
a, b 124 ± 17
b 136 ± 15
b
Hypothalamus 107 ± 20 55 ± 16
b 95 ± 9 127 ± 15
b
Corpus callosum 80 ± 19 41 ± 18 57 ± 14 87 ± 14
sensorimotor cortex 164 ± 27 74 ± 20 134 ± 15
b 140 ± 17
b
superiour colliculus 197 ± 27
a 70 ± 20
a, b 121 ± 12
b 130 ± 17
b
inferior colliculus 122 ± 5
a 71 ± 19
a, b 134 ± 21
b 67 ± 21
b
cerebellar cortex 127 ± 25
a 53 ± 14
a, b 116 ± 25
b 135 ± 27
b
dentate nucleus 133 ± 20
a 53 ± 14
a, b 127 ± 17
b 114 ± 20
b
facial nucleus 170 ± 31
a 70 ± 21
a, b 156 ± 32
b 131 ± 30
b
cochlear nucleus 150 ± 30
a 54 ± 15
a, b 150 ± 21
b 119 ± 25
b
vestibular nucleus 153 ± 18
a 75 ± 23
a, b 167 ± 22
b 130 ± 20
b
trigeminal nucleus 154 ± 22
a 65 ± 19
a, b 149 ± 22
b 124 ± 23
b
Values are expressed in ml/min/100 g and given as mean ± s.e.m.
a = significant difference between SAH and control groups,
b = significant difference between
SAH and SAH treated with SB386023-b 0 hr and 6 hr post SAH.
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nist PD123319). Treatment with SB386023-b given at 0
and 6 h after the SAH produced a significantly attenuated
Ang II induced response, compared to the rats with
induced SAH. Interestingly there was no significant differ-
ence in the contractile response between sham and
SB386023-b given at 0 and 6 h after the SAH (Figure 3C;
Table 4). However, SB386023-b treatment given 12 h after
the induced SAH did not show attenuated contractile
response as compared to SAH. Ang II did not induce
increased contractility in the BA after SAH. In the absence
of the AT2 receptor antagonist PD123319 there was no
increased contractile response to Ang II after SAH as
compared to sham (Figure 3D).
Table 3 Contractile effects of ET-1 and 5-CT in MCA and basilar arteries
Biphasic curve Sigmoidal curve
NK
+ mean ±
s.e.m
Emax 1(%) ±
s.e.m
Emax 2(%) ± s.e.m pEC50(1) ±
s.e.m
pEC50(2) ±
s.e.m
Emax (%) ±
s.e.m
pEC50 ±
s.e.m
ET-1 MCA
Sham 6 1.76 ± 0.57 152 ± 11 8.59 ± 0.14
SAH 7 1.95 ± 0.34 28 ± 8
a, b 148 ± 5 12.62 ± 0.23
a, b 9.35 ± 0.22
SAH+SB386023-b at 0 h 5 2.22 ± 0, 35 133 ± 5 8.87 ± 0, 15
SAH+SB386023-b after 6 h 9 1.81 ± 0, 27 176 ± 6 8.92 ± 0.13
SAH+SB386023-b after 12 h 5 1.45 ± 0.27 27 ± 7
a, b 149 ± 17 12.02 ± 0.39
a, b 9.13 ± 0.17
ET-1 BA
Sham 6 4.00 ± 0.58 119 ± 9 9.37 ± 0.10
SAH 6 3.70 ± 0.47 34 ± 5
a, b 126 ± 8 12.21 ± 0.15
a, b 9.67 ± 0.02
SAH+SB386023-b at 0 h 6 3.92 ± 0.45 124 ± 5 9.23 ± 0.16
SAH+SB386023-b after 6 h 6 4.23 ± 0.41 155 ± 10 8.80 ± 0.13
SAH+SB386023-b after 12 h 6 3.75 ± 0.32 29 ± 5 125 ± 5 12.41 ± 0.18 9.75 ± 0.23
5-CT MCA
Sham 6 1.67 ± 0.54 17 ± 6
a 42 ± 9
a 8.40 ± 0.14 6.08 ± 0.64
a
SAH 6 2.35 ± 0.40 35 ± 2
a, b 60 ± 3
a, b 8.47 ± 0.17 7.11 ± 0.01
a, b
SAH+SB386023-b at 0 h 5 2.45 ± 0.25 16 ± 5
b 43 ± 8 8.48 ± 0.13 6.39 ± 0.33
SAH+SB386023-b after 6 h 6 1.81 ± 0.27 21 ± 5
b 45 ± 17 8.43 ± 0, 11 6.33 ± 0.51
SAH+SB386023-b after 12 h 6 2.09 ± 0.35 50 ± 6 92 ± 9 8.37 ± 0.10 6.47 ± 0.02
5-CT BA
Sham 6 3.90 ± 0.62 18 ± 6
a 56 ± 9 8.00 ± 0.11
a 6.25 ± 0.15
SAH 8 4.00 ± 0.26 43 ± 6
a, b 64 ± 5 8.46 ± 0.21
a, b 6.68 ± 0.01
SAH+SB386023-b at 0 h 6 3, 89 ± 0.22 20 ± 4
b 47 ± 4 8.09 ± 0.21
a 6.12 ± 0.12
SAH+SB386023-b after 6 h 6 4.23 ± 0.41 12 ± 3
b 47 ± 9 7.92 ± 0.23
b 6.05 ± 0.44
SAH+SB386023-b after 12 h 6 3.75 ± 0.43 38 ± 5
b 55 ± 4 8.30 ± 0.19
a, b 6.48 ± 0.10
Responses were characterized by Emax values, expressed as percent of 63 mM K
+ -induced contraction, and pEC50 values (negative logarithm of the molar
concentration that produces half maximum contraction). Values are represented as mean ± s.e.m and n represents number of animal.
a = significant difference
between SAH and control groups,
b = significant difference between SAH and SAH treated with SB386023-b
Table 4 Contractile effects of Ang II in MCA
NK
+ mean ±
s.e.m
Emax (%) ±
s.e.m
pEC50 ±
s.e.m
Ang II after PD123319 MCA
Sham 6 2.34 ± 0.38 3 ± 2
a
SAH 6 1.33 ± 0.28 53 ± 12
a,b 7.95 ± 0.38
SAH + SB386023-b at 0 h
SAH + SB386023-b after 6 h
6
6
1, 74 ± 0.11
1.64 ± 0.12
11 ± 4
b
13 ± 5
b
SAH + SB386023-b after 12 h 6 1.47 ± 0.54 35 ± 5 8, 69 ± 0.14
Responses were characterized by Emax values, expressed as percent of 63 mM K
+ -induced contraction, and pEC50 values (negative logarithm of the molar
concentration that produces half maximum contraction). Values are represented as mean ± s.e.m and n represents number of animal.
a = significant difference
between SAH and control groups,
b = significant difference between SAH and SAH treated with SB386023-b
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To quantify mRNA for the ETA,E T B,A T 1,A T 2 and 5-
HT1B receptors, RT-PCR and real-time detection moni-
toring the PCR products was employed.
The standard curves for each primer pair had almost
similar slopes, demonstrating that EF-1, ETA,E T B,5 -
HT1B,A T 1 and AT2 cDNA were amplified with the
same efficiency (data not shown). In each PCR experi-
ment, a no template control was included, and there
were no signs of contaminating nucleic acids in the
samples. Since the results from the different brain
arteries examined MCA, BA and circle of Willis (n = 7-
10) were identical, they were grouped together in the
statistical analysis. The results showed that treatment
with SB386023-b inhibited the enhanced expression of
ETB,5 - H T 1B and AT1 receptor mRNA levels signifi-
cantly as compared to control (Figure 4A-C). There was
no difference in the expression of ETA and AT2 receptor
mRNA levels between the three groups sham, SAH and
SAH treated with SB386023-b (data not shown).
pERK1/2 expression examined by Western Blot
The phosphorylated ERK1/2 protein levels was investi-
gated by Western Blot.
The pERK1/2 protein levels were activated after SAH
(156 ± 14%) as compared to sham (100 ± 3%) The treat-
ment with the raf inhibitor SB386023-b at 6 h (88 ±
13%) after SAH prevented the pERK1/2 protein level
Figure 3 Concentration response curves elicited by cumulative application of ET-1, 5-CT and Ang II in rat cerebral arteries. (A) ET-1; BA,
(B) 5-CT; BA, (C) Ang II pretreated with PD123319; MCA and (D) Ang II; MCA. Effect of induced experimental SAH, SAH treated with raf inhibitor
SB386023-b at 0 h, 6 h and 12 h after SAH and sham operated rats are illustrated. The responses to ET-1, 5-CT and Ang II (pretreated with
PD123319) are clearly increased in the SAH compared to sham operated rats. The effects of SAH are clearly inhibited with use of SB386023-b
after 0 and 6 hour. Data are expressed as mean ± s.e.m, * P ≤ 0.05. * significantly difference between SAH and SAH treated with SB386023-b at
0 and 6 h. Statistical analyses were performed using Kruskal-Wallis non-parametric test together with Dunn’s post-hoc test.
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h after SAH did not attenuate the pERK1/2 protein
levels (120 ± 9%) (Figure 5A-B).
Protein expression examined with immunohistochemistry
The localization and activation of the protein levels was
examined by confocal microscopy and immunocyto-
chemistry using selective antibodies towards the phos-
phorylated ERK1/2, ETB,5 - H T 1B and AT1 receptors.
The results demonstrated that the pERK1/2, ETB,5 -
HT1B and AT1 receptors were all present in the cyto-
plasm of the cerebrovascular smooth muscle cells. Dou-
ble immunohistochemistry staining versus smooth
muscle actin, revealed their co-expression in the smooth
muscle cells were performed to verify the localization
and in the circle of Willis arteries, the MCA and the
BA, the microvessels in the brain (Figure 6). The ETB
receptor protein was expressed in the smooth muscle
cells and this signal was increased in SAH (167 ± 4%) as
compared to sham (100 ± 3%). Similarly the 5-HT1B
(180 ± 2%) and AT1 (168 ± 7%) receptor proteins were
expressed more in SAH as compared to sham (100 ±
7%) and (100 ± 7%); respectively (p < 0.05 for all).
Treatment with the raf inhibitor SB386023-b, starting
with administration at 0 h or 6 h after SAH blunted the
SAH induced upregulation of ETB (109 ± 5%), 5-HT1B
(121 ± 23%) and AT1 (105 ± 10%) receptor protein
levels in the smooth muscle cells (Figure 7A-L, Table 5).
However, when the SB386023-b treatment was started
12 h after the induced SAH it did not attenuate the
upregulated 5-HT1B (172 ± 25%) and AT1 (180 ± 15%)
receptor protein levels in the smooth muscle cell layer
as compared to the SAH (Figure 7A-L, Table 5). After
SAH the pERK1/2 level (188 ± 7%) was increased in the
smooth muscle cells as compared to sham (100 ± 3%).
Treatment with the ERK1/2 inhibitor at 0 h and 6 h
after starting the SAH prevented the pERK1/2 (102 ±
5%) activation (Figure 8, Table 5). SB386023-b given 12
Figure 4 Effect of treatment with the raf inhibitor SB386023-b in cerebral arteries on the mRNA levels of ETB,5 - H T 1B and AT1
receptors after experimental induced SAH in rats. (A) ETB, (B) 5-HT1B and (C) AT1. There are upregulations of the ETB, 5-HT1B and AT1
receptor mRNA levels in the SAH compared to the sham operated rats. Treatment with SB386023-b prevented the upregulations. Data were
obtained by real-time PCR and are expressed as mean ± s.e.m. values relative to EF-1 mRNA levels, n = 7-10, * P ≤ 0.05. Statistical analyses were
performed using Kruskal-Wallis non-parametric test together with Dunn’s post-hoc test.
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(Figure 8, Table 5).
In addition, as can be seen in Figure 7 and 8, the
upregulation was not confined only to the large cerebral
arteries but notable also in the brain parenchyma micro
vessels but not in the brain tissue proper, in neurons or
glial cells. Treatment with SB386023-b (0 and 6 h but
not 12 h) reduced also the microvessels receptor expres-
sion and the pERK1/2 in the smooth muscle cells.
Discussion
This study demonstrates that there is a clear association
between cerebrovascular receptor upregulation via tran-
scription involving activation of ERK1/2 and the subse-
quent reduction in CBF after SAH. Specific blockade of
the MAPK ERK1/2 activity with a raf inhibitor abolished
the vascular smooth muscle cell pERK1/2, the receptor
upregulation and normalised CBF and the neurology
score despite administration of the inhibitor as late as at
6 h after the start of the SAH. If the raf inhibitor was
given 12 h after initiating the SAH there were no signifi-
cant changes in CBF, neurology score, contractile recep-
tor upregulation and protein levels. There was, however
one exception, the protein level for ETB and the mRNA
levels were depressed also when the drug was given 12
h after the SAH.
A number of mechanisms and receptors have been
proposed to account for the late cerebral ischemia that
occurs after SAH with subsequent high morbidity. Here
we show that by intracisternal administration of a speci-
fic raf inhibitor this response can be modified which
implicates that cerebrovascular smooth muscle receptor
upregulation is an important part in the response to
SAH. The immunohistochemistry revealed that SAH
results in enhanced phosphorylation of pERK1/2 in the
smooth muscle cells and that this expression is normal-
ized by SB386023-b treatment. This confirms that speci-
fic inhibition of the ras/raf/MEK/ERK1/2 signaling
pathway in the cerebrovascular system is associated with
the receptor protein expression.
Figure 5 Effect of treatment with the raf inhibitor SB386023-b in cerebral arteries on the protein levels of pERK1/2 after SAH. There
are increased expressions of the pERK1/2 protein levels in the SAH compared to the sham operated rats. Treatment with SB386023-b after 6 h
prevented the increased protein expression. Data are presented as the pERK1/2/b-actin mean optical density ratio relative to control. Data are
expressed as mean ± s.e.m. * P ≤ 0.05.
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ment and testing of drugs that may antagonize putative
spasmogens, but to this date no effective drug exists
[1,6,25]. The latest in this line is the ET receptor
antagonist clazosentan [26]; the first preliminary study
revealed an effect on large artery vasospasm but had
no effect on the neurology deficit. The clinical trials
with the selective ETA antagonist clazosentan
demonstrated that clazosentan reduces the severity of
vasospasm following aneurysmal SAH; however, there
was no positive effect in the outcome of the patients.
This supports our view that the inhibition of only one
receptor system will not remedy other receptor sys-
tems involved. Instead, the mechanism responsible for
the receptor upregulation might be a more promising
target.
Figure 6 Double immunofluorescence staining for ETB,5 - H T 1B and AT1 and actin in smooth muscle cells of the basilar artery after
SAH. Photographs demonstrating the localization of ETB, 5-HT1B,A T 1, actin immunostaining, and their co-localization in smooth muscle cells
(yellow fluorescence in the merged picture). Scale bar, 50 μm.
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torial, we hypothesize that several receptors are involved
in the development and maintenance of this prolonged
pathological contraction [27]. Our studies have demon-
strated involvement of at least three groups of contrac-
tile cerebrovascular receptors in experimental SAH
[15,24,27-30] and in human stroke [31]; this alludes to
the possibility of the involvement of several receptor
systems in late cerebral ischemia and makes it attractive
to search for a key signal-transduction mechanism
involved in the upregulation process. We observed that
SAH results in receptor upregulation not only of the
large cerebral arteries but as shown in Figure 6 also of
vascular smooth muscle cell receptors in brain micro-
vessels. This latter observation might be of clinical rele-
vance since the clazosentan study (37) and the early
nimodipine study [32] revealed partial reversal of angio-
graphic vasospasm but no or minor effect on clinical
outcome.
Targeting only one of several important subtypes of
receptors such as those of endothelin-1, serotonin or
angiotensin II separately in clinical or experimental trials
might prevent cerebral ischemia to a certain degree as
seen in the literature, but treatments aimed at a
Figure 7 Sections from the basilar artery showing ETB, 5-HT1B and AT1 immunoreactivity in the smooth muscle cell layer.a )E T B; sham,
b) ETB; SAH, c) ETB; SAH treated with SB386023-b after 6 h, d) ETB; SAH treated with SB386023-b after 12 h, e) 5-HT1B; sham, f) 5-HT1B; SAH, g) 5-
HT1B; SAH treated with SB386023-b after 6 h, h) 5-HT1B; SAH treated with SB386023-b after 12 h, i) AT1; sham, j) AT1; SAH, k) AT1; SAH treated
with SB386023-b after 6 h, l) AT1; SAH treated with SB386023-b after 12 h. There are increased expressions of the ETB, 5-HT1B and AT1 receptor
protein levels in the SAH compared to the sham operated rats. Treatment with SB386023-b after 6 h prevented the increased protein expression
in the smooth muscle cells. Data were obtained with confocal microscopy.
Table 5 Activation of the different protein levels measured with immunohistochemistry in basilar artery after SAH
Sham SAH SAH + SB386023-b at 0 h SAH + SB386023-b after 6 h SAH + SB386023-b after 12 h
ETB
(%) ± s.e.m
100 ± 3 167 ± 4 107 ± 4 109 ± 5 93 ± 4
5-HT1B
(%) ± s.e.m
100 ± 7 180 ± 2 124 ± 25 121 ± 23 172 ± 25
AT1
(%) ± s.e.m
100 ± 7 168 ± 7 109 ± 8 105 ± 10 180 ± 15
pERK1/2
(%) ± s.e.m
100 ± 3 188 ± 7 101 ± 3 102 ± 5 167 ± 9
Values are expressed as percentage of control and given as mean ± s.e.m.
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since further possible receptors and inflammatory
mechanisms might be involved. In addition, the different
receptor antagonists have profound systemic vascular
effects which make their specific effects on the cerebral
circulation difficult to obtain. We have demonstrated
that upregulation of several of the contractile receptors
in the cerebral vasculature are interconnected by their
signal transduction pathways [19,28,29,33,34]. Hence,
blocking common signal transduction pathways can
simultaneously affect the signaling for production of
these receptor subtypes [35]. Cerebral ischemia elicits a
wide range of responses resulting in activation of a
number of intracellular pathways. In particular there is
an involvement of the mitogen-activated protein kinases
(MAPK) signalling pathway in cerebral vasospasm
[36-38].
The MAPK is a family of serine/threonine protein
kinases involved in cellular differentiation, proliferation
and survival [39,40]. Interestingly it is only the ERK1/2
pathway and not those of p38 or JNK that is active dur-
ing the first 24 h after experimental SAH [41]. JNK and
p38 are only activated at 48 h and this may relate to
inflammation and apoptosis which occur later in the
process. In addition, SB386023-b is selective for the
ERK1/2 pathway since it did not inhibit the JNK and p-
38 MAPK pathways [41]. Several other studies have
evaluated the effect of available raf inhibitors on cere-
brovascular G-protein coupled receptors [19,42,43]. In
additional the JNK, p38 and PKC inhibitors have been
tested. However the ERK1/2 seems to be more impor-
tant for the receptor upregulation [44,45]. The raf inhi-
bitor SB386023-b was the one showing the best
inhibiting effect on the cerebrovascular receptors and
the most specific for the MAPK pathway, which is the
reason why this inhibitor was chosen. In the present
study we have performed a study closely related to the
clinical reality. Thus, SB386023-b was found to have no
acute effect on the CBF, ICP or on the tone of the
MCA or on its contractility.
It is notable that the effect of the raf inhibitor was
equally strong when administration was started 6 h after
the SAH as when given at the time of the SAH (starting
at time 0 h), but had no significant effect when it was
given 12 h after the SAH. The present study was
designed to examine the possibility of a therapeutic win-
dow of relevance to the clinic. Interestingly, we observed
that the upregulation of receptors are located to the cer-
ebral blood vessels SMC (both large arteries and micro
vessels), with no signs of upregulation of either recep-
tors or activation of pERK1/2 in the adjacent brain tis-
sue. This is important since only a fraction of the SAH
patients have angiographic vasospasm [46]. In addition,
we observed that both the large cerebral arteries belong-
ing to the circle of Willis and the cerebral micro vessels
in the brain parenchyma are involved to the same extent
in cerebral ischemia after SAH. The raf inhibitor
SB386023-b affects all vessel types. One possibility may
be that the micro vessels are involved in the ischemia
that occurs without angiographic vasospasm and the lar-
ger arteries might be involved in ischemia where vasos-
pasm takes place or can be visualized angiographically.
Conclusion
In conclusion, we have provided two important observa-
tions: First blockade of pERK1/2 with a raf inhibitor in
the cerebrovascular smooth muscle cells prevents the
upregulation of contractile receptors and the associated
reduction in the regional CBF and neurology score after
SAH. Second the two phenomena are associated and
putatively treatable also in the clinical setting since
administration of the raf inhibitor first applied 6 h after
the induction of the SAH showed to have effect. There-
fore, we suggest that this is a novel target for treatment
Figure 8 Sections from the basilar artery showing pERK immunoreactivity in the smooth muscle cell layer. a) pERK1/2; sham, b) pERK1/2;
SAH, c) pERK; SAH treated with SB386023-b after 6 h, d) pERK; SAH treated with SB386023-b after 12 h, There are increased expressions of the
pERK1/2 protein levels in the SAH compared to the sham operated rats. Treatment with SB386023-b after 6 h prevented the increased protein
expression in the smooth muscle cells. Data were obtained with confocal microscopy.
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after SAH.
Methods
All animal procedures were carried out strictly within
national laws and guidelines and approved by the Dan-
ish Animal Experimentation Inspectorate and the Ethical
Committee for Laboratory Animal Experiments at the
University of Lund.
Rat subarachnoid hemorrhage model
Subarachnoid hemorrhage was induced by a model ori-
ginally devised by Svendgaard et al [47] and carefully
described by Prunell et al [48]. Svendgaard has in an
elegant series of studies carefully analysed the correla-
tion between amount of blood, angiographic vasocon-
striction, CBF and cerebral metabolism. In a previous
study using the same SAH model Delgado et al [49]
have revealed a biphasic vasospasm in angiographic
examinations of the arteries with a maximal acute vaso-
constriction at ten minutes and a late maximal constric-
tion at two days after SAH.
Male Sprague-Dawley rats (350-400 g) were anaesthe-
tized using 5% halothane (Halocarbon Laboratories,
River Edge, New Jersey) in N2O/O2 (30:70). The rat was
intubated and artificially ventilated with inhalation of
0.5-1.5% halothane in N2O/O2 (70:30) during the surgi-
cal procedure. The depth of anaesthesia was carefully
monitored and the respiration checked by regularly
withdrawing arterial blood samples for blood gas analy-
sis (Radiometer, Copenhagen, Denmark). An electric
temperature probe was inserted into the rectum of the
rat to record the temperature, and found to be main-
tained at 37°C. An arterial catheter was placed in the
tail artery to measure blood pressure and a catheter to
monitor intracranial pressure (ICP) was placed in the
subarachnoid space under the subocciptal membrane.
At either side of the midline of the skull, 3 mm from
the midline and 4 mm anteriorly from the bregma,
holes were drilled through the skull bone down to the
dura mater (without perforation) allowing the placement
of two laser-Doppler flow probes to measure cortical
CBF. Finally, a 27 G blunt canula with side hole was
introduced 6.5 mm anterior to bregma in the midline at
an angle of 30° to the vertical. With the aperture point-
ing to the right, the needle was lowered until the tip
reached the skull base 2 to 3 mm anterior to the
chiasma. After 30 minutes of equilibration 250 μlo f
blood was withdrawn from the tail catheter and injected
intracranially via this canula at a pressure equal to the
mean arterial blood pressure (MABP) (80-100 mmHg).
Subsequently the rat was kept under anaesthesia for
another 60 minutes to allow recovery from the cerebral
insult after which catheters were removed and incisions
closed. The rat was then revitalized and extubated. A
subcutaneous injection of carprofen (4.0 mg/kg) (Pfizer,
Denmark) was administered and the rat was hydrated
subcutaneously using 40 ml isotonic sodium chloride at
the end of the operation and at day one. During the per-
iod, the rat was monitored regularly, and if showing
severe distress the animal was prematurely killed. In
addition, a series of sham-operated rats were prepared.
Two types of sham animals were studied; no fluid injec-
tion or injection of saline (250 μl) during 15 min to
avoid any change in ICP [50]. Since both procedures
revealed the same outcome, they were grouped together
in the statistical analysis. After two days either autora-
diography measurements or harvesting of vessels were
done (see below for details)
Neurology scoring
All surviving animals were neurologically examined
using an established scoring system of 0 -5 (Table 1)
[21,22]. The animals were tested on the day before sur-
gery. On day 1 and 2 after surgery each animal was
tested twice. All animals were graded by personnel
blinded to the experimental groups of the animals, and
subjectivity in the observations was reduced by the
involvement of two observers in the testing of each
animal.
Measurement of the effect of the raf inhibitor on the
cortical CBF and ICP
This group of animals went through the same procedure
as the above-mentioned SAH animals until the injection
of blood. To investigate the effect of the raf inhibitor on
the cortical CBF and ICP 20 μl; 10
-6 M of SB386023-b
(a kind gift from Dr A A Parsons, GSK, UK) was given
a tt h et i m ep o i n t0ha n d6ha f t e rt h ei n d u c e dS A H .
The SB386023-b was injected intracisternally via the
occipital membrane into the cisterna magna. The corti-
cal CBF and ICP were measured during the entire time
period 0-7 h after the SAH. After the experiment the
animals were decapitated. Control sham animals
received the same volume of saline.
Rat subarachnoid hemorrhage model with raf inhibition
This group of animals went through the same procedure
as the above-mentioned SAH animals. In addition they
were treated with 20 μl; 10
-6 M of SB386023-b or the
same volume of vehicle. Three groups of treated animals
were examined; (i) 20 μl; 10
-6 M SB386023-b was
repeatedly injected intracisternally at 0, 6, 12, 24 and 36
h after the induced SAH (ii) 20 μl; 10
-6 M SB386023-b
was repeatedly injected intracisternally at 6, 12, 24 and
36 h after the induced SAH or (iii) 20 μl; 10
-6 M
SB386023-b was repeatedly injected intracisternally in
the cistern magna at 12, 24 and 36 h after the induced
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detailed work on isolated arteries [19] and in vivo study
with SAH and ERK1/2 inhibition [28]. The dose used
was chosen at near maximum inhibition and calculation
of cerebrospinal fluid volume/turn over.
Autoradiographic measurements of regional CBF
Regional and global cerebral blood flow was measured
by a model originally described by Sakurada [51] and
modified by Gjedde [52].
In brief, after 48 hours of observation rats in the var-
ious groups (sham, SAH, SAH + vehicle and SAH trea-
ted with the raf inhibitor) were anaesthetized using 5%
halothane in N2O/O2 (30:70). The animal was intubated
and artificially ventilated with inhalation of 0.5 -1.5%
halothane in N2O/O2 (70:30) during the surgical proce-
dure. The anaesthesia and the respiration were moni-
tored by regularly withdrawing arterial blood samples
for blood gas analysis (Radiometer AS, Denmark). A
catheter to measure MABP was placed in the right
femoral artery and a catheter for blood sampling was
placed in the left femoral artery. This catheter was con-
nected to a constant velocity withdrawal pump (Harvard
apparatus 22, USA) for mechanical integration of tracer
concentration. In addition, a catheter was inserted in
one femoral vein for injection of heparin and for infu-
sion of the radioactive tracer. The MABP was continu-
ously monitored with a Powerlab Unit (ADInstruments,
UK). A temperature probe was inserted into the rectum
of the rat to record the temperature, which was regu-
larly maintained at 37°C. The hematocrit was measured
by a hematocrit centrifuge (Beckman Microfuge 11,
USA). After 30 minutes of equilibration a bolus injec-
tion of 50 uCi of
14C-iodoantipyrine 4[N-methyl-
14C]
(Perkin-Elmer, Boston, USA) was given i.v. Arterial
blood (122 μl) was withdrawn over 20 seconds. Immedi-
ately after this the animal was decapitated, the brain
removed and immersed in isopentane chilled to - 50°C.
The arterial blood sample was transferred to liquid scin-
tillation counting vials containing 1 ml mixture of
Soluene-350 and Isopropanol (1:1). The b-radioactivity
scintillation counting was performed on the samples
with a program that included quench correction (Pack-
ard 2000 CA, Denmark). The
14C activity in the tissue
was determined after sectioning the brain in 20 μms e c -
tions at -20°C in a cryostat (Wild Leitz A/S, Glostrup,
Denmark). The sections were exposed to x-ray films
(Kodak, Denmark) together with
14C methylmethacrylate
standards (Amersham Life Science, England) and
exposed the films for 20 days. Densities of the autora-
diograms were measured with a Macintosh computer
equipped with an analog CF 4/1 camera (Kaiser, Ger-
many) and a transparency flat viewer (Color-Control
5000, Weilheim, Germany). The
14Cc o n t e n tw a s
determined in several brain regions (see Table 2). The
CBF was calculated from the brain tissue
14C activity
determined by autoradiography using Gjedde et al.’s
equation [52].
Harvest of cerebral arteries
After 48 hours of observation sham, SAH treated with
SB386023-b or SAH + vehicle operated rats (see above
SAH model) were anaesthetized with CO2 and decapi-
tated. The brains were quickly removed and chilled in
ice-cold bicarbonate buffer solution. Under a dissection
microscope, the middle cerebral artery (MCA), the basi-
lar artery (BA) and circle of Willis were dissected out.
The MCA and BA were immediately mounted in myo-
graphs for in vitro pharmacology or snap frozen at -80°
C and examined by real-time PCR or
immunohistochemistry.
In vitro pharmacology myograph experiments
For contractile experiments a sensitive myograph was
used for recording the isometric tension in isolated cere-
bral arteries [53,54]. The vessels were cut into 1 mm
long cylindrical segments and mounted on two 40 μm
in diameter stainless steel wires in a Myograph (Danish
Myo Technology A/S, Denmark). One wire was con-
nected to a force displacement transducer attached to
an analog-digital converter unit (ADInstruments,
Oxford, UK). The other wire was connected to a micro-
meter screw, allowing fine adjustments of vascular tone
by varying the distance between the wires. Measure-
ments were recorded on a computer by use of a Power-
Lab unit (ADInstruments). The segments were
immersed in a temperature controlled buffer solution
(37°C) [50]. The vessels were stretched to an initial rest-
ing tone of 2 mN and then allowed to stabilize at this
tone for 1 hour. The contractile capacity was deter-
mined by exposing the vessels to an isotonic solution
containing 63.5 mM of K
+, obtained by partial change
of NaCl for KCl in the above buffer. The contraction
induced by K
+ was used as reference for the contractile
capacity [54]. Only vessels responding by contraction of
at least 2.0 mN to potassium for BA and 0.8 mN to
potassium for MCA were included in the study. The
presence of the endothelium was checked by precon-
tracting the vessel using 5-HT (10
-6.5 M) (Sigma, St
Louis, USA) and subsequently exposing the segments to
carbachol (10
-5 M) (Sigma, St Louis, USA). A relaxant
response of the precontracted tension was considered
indicative of a functional endothelium [24].
Concentration-response curves were obtained by
cumulative application of 5-CT (Sigma, St. Louis, USA)
in the concentration range 10
-12 to 10
-5 M, ET-1 (Ana-
Spec, San Jose, USA) in the concentration range 10
-14
to 10
-7 M, SB386023-b (a kind gift from Dr A A
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-12 to
10
-6 M and Ang II (Sigma, St. Louis, USA) in the con-
centration range 10
-12 to 10
-6 M. Before application of
Ang II the arteries were pretreated with the AT2 recep-
tor antagonist PD123319 (10
-5.5 M) for 30 minutes
(Sigma, St. Louis, USA). The concentration-response
curves for SB386023-b were investigated both with and
without precontraction with 5-HT (10
-6.5 M) (Sigma, St
Louis, USA).
RNA isolation
To quantify mRNA for the ETA,E T B,A T 1,A T 2 and 5-
HT1B receptors, RT-PCR and real-time detection moni-
toring the PCR products was employed.
Total cellular RNA was extracted from BA, MCA and
circle of Willis using the Trizol RNA isolation kit (Invi-
trogen, USA) following the suppliers instructions.
Briefly, the arteries were homogenized in 1 ml of Trizol
(Invitrogen, Sweden) by using a TissueLyser (VWR,
Sweden). Subsequently 200 μl of chloroform was added
and the samples were incubated in room temperature
for 3 min, followed by centrifugation at 15000 g for 15
min at 4°C. The supernatant was collected and the
organic phase discarded. 200 μl of chloroform was again
added to remove all traces of phenol and the samples
were centrifuged at 15000 g for 15 at 4°C. The aqueous
supernatant was again collected and to precipitate the
RNA equal amount of isopropanol was added and the
samples incubated overnight at -20°C.
Subsequently, the RNA was centrifuged at 15000 g for
20 min at 4°C. The supernatant was discarded and the
resulting pellet was washed with 75% ethanol, air dried
and re-dissolved in diethylpyrocarbonate treated water.
Total RNA was determined using a GeneQuant Pro
spectrophotometer measuring absorbance at 260/280
(Amersham Pharmacia Biotech, Uppsala, Sweden).
Real-time PCR
Reverse transcription of total RNA to cDNA was carried
out using the Gene Amp RNA kit (Perkin-Elmer
Applied Biosystems, USA) in a Perkin-Elmer 2400 PCR
machine at 42°C for 90 min and then 72°C for 10 min.
The real-time quantitative PCR was performed with the
G e n e A m pS Y B RG r e e nP C Rk i t( P EA p p l i e dB i o s y s -
tems) in a Perkin-Elmer real-time PCR machine (Gen-
eAmp 5700 sequence detection system). The above
synthesized cDNA was used as a template in a 25 μl
reaction volume and a no template was included in all
experiments. The system automatically monitors the
binding of a fluorescent dye to double-strand DNA by
real-time detection of the fluorescence during each cycle
of PCR amplification. Specific primers for the rat ETA,
ETB,A T 1,A T 2 and 5-HT1B receptor and house keeping
gene elongation factor-1 (EF-1) were designed by using
the Primer Express 2.0 software (PE Applied Biosystems)
and synthesized by TAG Copenhagen A/S (Copenhagen,
Denmark). For the primer sequence, refer to our pre-
vious studies [27].
The housekeeping gene EF-1 is used as a reference,
s i n c ei ti sc o n t i n u o u s l ye x p r e s s e dt oac o n s t a n ta m o u n t
in cells.
The PCR reaction was carried out as follows: 50°C for
2 min, 95°C for 10 min and the following 40 PCR cycles
with 95°C for 15 sec and 60°C for one min. Each sample
was examined in duplicates. To verify that each primer-
pair only generated one PCR product at the expected
size a dissociation analysis was performed after each
real-time PCR run. A blank control (without template)
was used in all experiments. To prove that the cDNA of
EF-1 and the ET, AT and 5-HT1B receptors were ampli-
fied with a similar efficacy during real-time PCR, a stan-
dard curve were made.
Tissue Lysis and Protein Content Determination
After dissection of the circle of Willis arteries, the ves-
sels were collected and placed on ice, homogenized in
lysis-buffer with protease- and phosphatase inhibitors.
After 20 min incubation in lysis buffer on ice, homoge-
nates were centrifuged at 4500 g for 10 min at 4°C and
supernatant collected. Total protein concentration was
determined using a BioRad DC kit (Hercules, CA, USA)
and measuring absorbance at 750 nm on a Genesys 10
spectrophotometer (Thermo, Waltham, MA, U.S.A.).
Lysates were used immediately or stored at -80°C.
Western Blot Analysis
Proteins of interest were evaluated in circle of Willis
arteries from the various groups.
Lysates were dissolved in Tris-glycine SDS sample
buffer and boiled for 5 min. Equal amounts of protein
(50 μg/lane) were loaded on a 8% Tris-glycine gel (Invi-
trogen A/S, Taastrup, Denmark) and separated by SDS-
PAGE. Molecular weight markers (New England Bio-
Labs, Ipswich, MA, USA) were loaded on each gel for
protein band identification. After separation, proteins
were transferred to a nitrocelullose membrane (BioRad,
Hercules, CA, USA). Subsequently the membrane was
blocked with 6.5% non-fat milk in Tween-TBS (T-TBS)
overnight 4°C. Membranes were then incubated with the
primary antibody of interest: pERK1/2 (1:5000 dilution;
Promega, Madison, WI, U.S.A.) or b-actin (1:1000 dilu-
tion; Sigma, Saint Louis, USA) for 1 h at 37°C, followed
by 3 × 5 min wash with T-TBS. Subsequently the mem-
branes were incubated with the appropriate secondary
antibody: goat anti-rabbit IgG-horseradish peroxidase or
goat anti-mouse IgG-horseradish peroxidase (1:5000;
Pierce, Rockford, IL, U.S.A) for 1 h at room tempera-
ture, followed by 5 × 5 min wash with T-TBS. Levels of
Ansar et al. BMC Neuroscience 2011, 12:107
http://www.biomedcentral.com/1471-2202/12/107
Page 14 of 17b-actin were used to confirm equal loading of the lanes.
The membranes were developed using the Supersignal
Dura kit (Pierce, Rockford, IL, U.S.A.) and visualized
using a Fujifilm LAS-1000 Luminiscent Image Analyzer
(Stamford, CT, U.S.A.).
Immunohistochemistry
For immunohistochemistry the indirect immunofluores-
cence method was used. The BA, with surrounding
brain tissue were dissected out and frozen in ice cold
isopentane. They were then sectioned into 10 μmt h i c k
slices in a cryostat. The cerebral artery crysections were
fixed for 10 minutes in ice cold acetone and thereafter
rehydrated in phosphate buffer solution (PBS) contain-
ing 0.25% Triton X-100 for 15 minutes. The tissue was
then permeabilized and blocked for 1 hour in blocking
solution containing PBS, 0.25% Triton X-100, 1% BSA
and 5% normal donkey serum. The sections were incu-
bated over night at 4°C with the following primary anti-
bodies: rabbit antihuman ETB (IBL, 16207), diluted
1:400, goat anti mouse 5-HT1B (Santa Cruz Biotechnolo-
gies, sc-1461), diluted 1:100, AT1 (Santa Cruz Bio-
technologies), diluted 1:100, mouse anti rat CD31
(Serotec, MCA1746), diluted 1:200, rabbit antiphospho
ERK 1/2 MAPK (Cellsignalling #4376) diluted 1:50. and
mouse anti rat smooth muscle actin (Serotec,
MCA1905T) diluted 1:100. All dilutions were done in
PBS containing 0.2% Triton X- 100, BSA 1% and 2%
normal donkey serum. Sections were subsequently
washed with PBS and incubated with secondary anti-
body for 1 hour at room temperature. The secondary
antibody used were donkeyantimouse Cy™5 conjugated
(JacksonImmunoResearch, 715-175-150), donkeyantirab-
bit Cy™3 conjugated (JacksonImmunoResearch, 711-
165-152) diluted 1:200 in PBS containing 0.2% TritonX-
100 and BSA 1%. The sections were washed subse-
quently with PBS and mounted with permafloure
mounting medium (Beckman coulter, PN IM0752). The
same procedure was used for the negative controls but
primary antibodies were omitted. The immunoreactivity
of the antibodies were visualized and photographed with
a Nikon Eclipse E800 microscope fitted with fluores-
cence optics at the appropriated wavelength.
Calculations and statistics
Data are expressed as mean ± standard error of the
mean (s.e.m.), and n refers to the number of rats. Statis-
tical analyses were performed with Kruskal-Wallis non-
parametric test with Dunn’s post-hoc test, where P <
0.05 was considered significant.
In vitro Pharmacology Contractile responses in each
segment are expressed as percentage of the 63.5 mM K
+
induced contraction. Emax value represents the maxi-
mum contractile response elicited by an agonist and the
pEC50 the negative logarithm of the drug concentration
that elicited half the maximum response. For biphasic
responses, Emax(1) and pEC50(1) describes the high affi-
nity phase and Emax(2) and pEC50(2) describes the low
affinity phase.
Real-time PCR Data were analysed with the compara-
tive cycle threshold (CT) method [30]. The CT values of
EF-1 mRNA were used as a reference to quantify the
relative amount of ETA,E T B,A T 1,A T 2 and 5-HT1B
mRNA. The relative amount of mRNA was calculated
with the CT values of ETA,E T B,A T 1,A T 2 and 5-HT1B
receptor mRNA in relation to the CT values of EF-1
mRNA in the sample by the formula X0/R0 =2
CtR-CtX,
where X0 is the original amount of target mRNA, R0 is
the original amount of EF-1 mRNA, CtR is the CT value
for EF-1 and CTX is the CT value for the target.
Western Blot Cerebrovascular protein lysates from the
different groups were compared. Cerebral arteries from
2 animals were pooled for each group of experiment
and each experiment was repeated 3 times. Quantitation
of band density was performed with the electrophoresis
computer analysis program Fujifilm Science Laboratory
Image Gauge 4.0. The immunoblot optical density
values were determined with repeated measurement and
presented as percentage activity in the treated groups
compared with the sham in which the sham group was
set to 100%.
Immunohistochemistry The images were analysed using
the ImageJsoftware http://rsb.info.nih.gov/ij. The fluores-
cence in 4-6 different areas in each artery was measured
and a mean value was calculated. These values are pre-
sented as percentage fluorescence in the SAH groups
compared to the sham group, where the sham group is
set to 100%.
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